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1 Abstract
In this paper we simulate the wild type MAPK pathway response to twelve in silico drugs
that were previously found to reduce elevated phosphorylated ERK levels (ERK*) in 40 top
ranked mutations in a model of the MAPK signal transduction pathway. We find that a
subset of the simulated drugs (notably those targeting GEF and the Gαβγ G-protein trimer)
were able to effectively inhibit the elevated ERK* levels of the mutated pathways, whilst
simultaneously eliciting only minimal inhibition of the wild type pathway ERK* response to
EGF stimulation.
2 Background and Methodology
In previous work [1, 2], we developed a ranked list of 40 mutations most likely to cause
elevated ERK* levels in an ODE model of the MAPK signal transduction pathway [3]. Sub-
sequently, we compiled a ranked list of inhibiting drugs that competitively bind to pathway
participants, removing them from further pathway interaction and leading to reduction in
steady state ERK* levels in these mutated pathways [4, 5].
In this work, we investigate balancing the effects of these ERK* reducing drugs on the
mutated pathways with their effects on the non-perturbed wild type MAPK pathway, with
the intention of finding a regime that still allows for normal growth factor (EGF) signaling
functionality and ERK* response in the wild type pathway with minimal reduction in drug
efficacy. The investigated drug targets consist of Raf, Ras, the Gαβγ G-protein, GEF, MEK,
ERK, PLA2, PKC, PLCβ, PLCγ , and two calcium channels. After running simulations of
the drugged wild type pathway (under a 10 min, 3nM EGF stimulation) through a wide
parameter space of drug dissociation constant kd = kb/kf and initial drug concentration C0,
we extract the peak ERK* values for each simulation and compare them to the previously
found steady state ERK* levels of the mutated pathways. ERK* levels below 0.002µM
are considered basal, and pathways with steady state ERK* levels below this threshold
are considered to be inactive, or non-signaling. Drugs that could deactivate the mutated
pathways, yet imparted only minimal effect on the wild type pathway were ranked higher
that drugs that could not as clearly distinguish between mutated and wild type pathways.
3 Results
While all drug targets demonstrated some ability to differentiate between mutated and wild
type pathways, the most promising drug target in terms of its effect on the wild type pathway
was GEF (Fig 1). At a concentration of 0.0316µM , for all kd < 0.00316µM , the drugs
targeting GEF elicited the inactivation of 39 out of 40 mutated pathways. Simultaneously,
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Figure 1: Comparison of simulated wild-type pathway ERK* response (crosses, left axis) and
histogram of mutated pathway deactivation (stair step, right axis) by drugs targeting GEF.
Simulations are run through the range of concentrations 10−3µM to 1µM . The dissociation
constant of the drug/target interaction is kd = 10
−4µM .
this drug reduced the wild type ERK* response peak to EGF stimulation by only 0.2nM , a
reduction of less than 3% from the non-drugged ERK* response.
The next highest performing drug target is the Gαβγ G-protein which, at a drug concentration
of C0 = 0.2512µM for all kd < 0.01µM , elicited the inactivation of 36 out of 40 mutated
pathways. At the same C0 value, the drug reduced the wild type ERK* response peak by
0.81nM , or just under 11% of the peak value.
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